iBio, Inc.’s Post

3 years ago, I discovered BioRender, and it felt like a dream come true for someone who appreciates the visual side of things. By seamlessly blending science, art, and creativity, BioRender allows us to bring complex biological concepts to life. I'm excited to share our latest publication, where I had the opportunity to create a scientific illustration that summarizes the innovative biosensing methodologies developed for the detection of HCC (Hepatocellular Carcinoma) biomarkers. This publication highlights the potential of these advanced approaches to improve early diagnosis and monitoring of this complex disease. https://lnkd.in/dHuMTsT5 #BioRender #ScienceVisualization #CreativeScience #HCC #Biomarkers #MedicalResearch #research #KFSHRC

Enjoyed my first time attending #CGMesa24 in PHX with Gina Black, MBA. Great to learn more about ongoing efforts to make cell and gene treatments further accessible (as thoughtfully as possible) to patients, physicians, and institutions across the board. We were fortunate enough to meet some incredibly smart and passionate people who were already hard at work on it. Charismatic speaker panels and moderators drove well-considered discussions with thoughtleaders from all stakeholders. There was also an incredible patient testomonial that was a stark reminder on how much extra room there is to enhance the patient experience. Looking forward to attending future events, from a market access viewpoint some topics really hit home: ⁃ Rethinking of patient journeys beyond traditional parameters ⁃ Downstream benefits of market access strategy 1-2 years ahead of PDUFA / prior to publication of pivotal study ⁃ Urgency to ease academic/community hospital burdens of all imagineable forms so they can instead focus on patient care (for example: product portals are necessary, and do work fine, but yet apparently are not a favorite thing?🙂)

Looking back at an insightful panel discussion on the "Market Access for Advanced Diagnostics and Comprehensive Genomic Profiling" at this year's World Evidence, Pricing and Access Congress: ⚡ Comprehensive #Genomic Profiling (CGP) offers clear clinical and economic value for both #patients and #healthcare systems, however access to CGP still remains limited, compared to broader availability of single gene and panel testing.   💎 There is a critical lack of awareness of the value of #AdvancedDiagnostics and #GenomicTesting overall. Reimbursement pathways are too slow, causing delayed #access for European patients. Even when testing is reimbursed, the funding is frequently insufficient to ensure access for all patients. This will need to change in order to unlock the full potential of #PersonalisedMedicine.   🤝 With the complexity of the issues at hand, no single country or stakeholder will be able to address them alone. Coalitions such as the European Coalition for Access to Comprehensive Genomic Profiling (ECGP) are needed to facilitate #collaboration between stakeholders. ECGP aims to increase access to CGP by sharing #BestPractices across Europe, as well as #evidence on the clinical and economic value of CGP with payers.   Thanks to Matias Olsen, Nidhi Dani, Dianne Baunbaek, Benjamin Gannon, Ivana Cattaneo and Pieter Drost PharmD MSc for this insightful discussion! Let's continue the dialogue and action towards breaking down barriers and unlocking the full potential of genomic testing in personalised medicine! 💪 #ECGP #EquitableAccess #Genomics #ADx #CGP #Innovation

🌍 Outdated diagnostic methods for bacterial infections and certain cancers are holding back the potential for early and precise treatment in Ethiopia. But genomics offers a transformative alternative, delivering diagnostics that are faster, more accurate, and personalized to individual patient needs. At Retina Pharmaceuticals, we’re proud to be collaborating with Illumina to introduce advanced sequencing technologies and we are also excited tio announce that we are preparing to provide custom genomic libraries to Ethiopia's healthcare landscape. 🚀 This initiative is set to empower the healthcare community by addressing critical diagnostic challenges and supporting precision medicine. We invite organizations, researchers, and healthcare stakeholders to join us on this transformative journey and explore partnership opportunities that drive impactful change. 📞 For more information, please connect with Sisay Alemu at Retina Pharmaceuticals +251925528360. Let’s build a healthier future together, one genome at a time! #Genomics #HealthcareInnovation #PrecisionMedicine #Diagnostics #RetinaPharma #Illumina #EthiopianHealthcare #Partnerships #PublicHealth #EastAfricaGenomics

A very topical panel - especially with the rise of advanced diagnostics, such as #genomesequencing tools, the advent of #geneediting technologies and the push for #precisionmedicine. Once again such tools and initiatives fall on the #marketaccess sword. Best practices on evidence generation and HTA assessment are key and should be broadly aligned to increase certainty for companies and developers. And, in light of the ongoing EU Pharmaceutical Review, these topics and the interplay of IVDs and the clinical trial framework should be carefully considered. On the plus side, the UK's initiative Genome UK is a step in the right direction (https://lnkd.in/dHY464kq).

Heart failure – almost in the clinical phase. Further in the pipeline: 👉 lung fibrosis 👉 tumor microenvironment 👉 liver  👉 pancreas 👉 kidney and then… “We're really excited about the potential because we think this platform can be deployed for essentially any disease,” Samir Ounzain , the CEO of HAYA Therapeutics said on the new X-Health.show episode and Aleksandra Jani’s jaw dropped to the floor. The key is in the dark genome. “But you know, we need as a community, we need a paradigm shift in how we think about biology because you'd probably be surprised to hear there was a very strong conviction that 98% of the genome is junk– in academia.” And this is what we start this episode from – the fascinating history of the junk genome turning into dark genome turning into, as HAYA calls it now, regulatory genome. Hit the link in the comments to 🎧 hear about 💡 the richness of the regulatory genome 💡 its function: as a kind of software for the human body 💡 RNA therapies that are targeted, non-toxic, fast in development 💡 an absolutely new approach to drugs HAYA Therapeutics is a Swiss startup that created the world’s largest long non-coding RNA database. These RNAs play a critical function in the dark genome. They selected one of them, called Wisper, to develop a highly targeted drug to address cardiovascular disease. They are based in both Lausanne and San Diego. Thank you François Capel and Innovaud for connecting us 🙏 #biotech #heartfailure #RNA #futureofhealthcare #healthcareinnovation #swissstartups #xhealth BioAlps - Swiss Health Valley Biopôle Lausanne Buzzsprout

🔥PRESS RELEASE 📰 Compass Bioinformatics has partnered with Advanced Genomics APAC to expand rare disease and cancer testing throughout Japan, Korea, Southeast Asia, and the Australia-New Zealand region. Through this collaboration, our #InheriNext® 𝗮𝗻𝗮𝗹𝘆𝘀𝗶𝘀 𝘀𝗼𝗳𝘁𝘄𝗮𝗿𝗲 will work alongside their #Cell3™ 𝗧𝗮𝗿𝗴𝗲𝘁: 𝗡𝗲𝘅𝗼𝗺𝗲 𝗣𝗮𝗻𝗲𝗹, creating a comprehensive solution from genetic data preparation to analysis. This #partnership is designed to accelerate diagnostics for hereditary rare diseases, addressing long diagnostic journeys faced by patients. By combining expertise, we aim to improve diagnostic efficiency and accuracy across #Asia_Pacific #healthcare institutions, bringing timely solutions and hope to patients and medical professionals. Original article: https://lnkd.in/gXazKTGX #CompassBioinformatics #InheriNext® #AdvancedGenomicsAPAC #Nonacus #Cell3 #Nexome #Target #Panel #RareDisease #Diagnostics #Cancer #CancerTesting #PrecisionMedicine #Healthcare #Innovation #AsiaPacific #Software #Analysis #Biotech #NGS #Genomic #Hereditary #PersonalizedMedicine #Bioinformatics #Medicine #Clinical

🔔 Only a few weeks left to get early bird discount. This is the place to be, to learn about #Cell and #genetherapy and how existing technology can be applied to solve for a rare genetic disease. If you have an interest or asset in #CysticFibrosis, #bronchiectasis, #PCD, Idiopathic Pulmonary Fibrosis (IPF) and Progressive Pulmonary Fibrosis (PPF) or other rare respiratory diseases, then join us on 1st October at The Francis Crick Institute. 💊 This event is for #biotech, #pharma and #investors with an interest in #rare and #orphandrugs across the continuum of development from #pipeline to #market launch. Network with leaders in #genomics, #translational medicine, #peadiatric respiratory research.

New Breakthrough in Parkinson's Biomarker Research! Exciting news from the research community! Professor Francisco Ciruela from UB and IDIBELL has unveiled a potential biomarker to track Parkinson's disease progression. This discovery could revolutionise the way we manage and treat this complex condition. #Parkinsons #Biotechnology #LifeSciences #LifeSciencesRecruitment

🚀 Exciting Partnership Announcement! 🚀 🔬 Boehringer Ingelheim partners with UK biotech Ochre Bio to tackle chronic liver disease. 💰 Up to $1bn partnership to develop treatments harnessing liver's regenerative capacity. 🔍 Ochre Bio's approach: - Analysing thousands of human livers to understand disease causes. - Studying RNA changes to extend lifespan of transplanted livers. - Aiming to 'nudge' liver cells to regenerate. 💡 Partnership aims to address unmet needs in advanced liver disease. 👨🔬 Boehringer sees Ochre Bio's genomics expertise as key to uncovering regenerative pathways. Exciting times ahead in liver disease treatment! 🌟 #machinelearning #biotech #drugdiscovery